EcoDrugPlus

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSSTOG00000010596
Gene Symbol: PSMA4
4 Cross references
241 Possible Orthologues:

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSSTOG00000011225
Gene Symbol: PSMA5
3 Cross references
209 Possible Orthologues:

Proteasome 20s Subunit Alpha 7

Ensembl ID : ENSSTOG00000012489
Gene Symbol: PSMA7
3 Cross references
151 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSSTOG00000015708
Gene Symbol: PSMA8
4 Cross references
197 Possible Orthologues:

Proteasome 20s Subunit Beta 1

Ensembl ID : ENSSTOG00000010581
Gene Symbol: PSMB1
3 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSSTOG00000002011
Gene Symbol: PSMB10
3 Cross references
171 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSSTOG00000001795
Gene Symbol: PSMB2
3 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSSTOG00000014258
Gene Symbol: PSMB3
4 Cross references
234 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSSTOG00000012054
Gene Symbol: PSMB4
3 Cross references
213 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSSTOG00000007134
Gene Symbol: PSMB5
3 Cross references
218 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSSTOG00000014871
Gene Symbol: PSMB6
2 Cross references
214 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSSTOG00000013826
Gene Symbol: PSMB7
3 Cross references
218 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).